Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma.
Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma.
复制标题
作者：
乳腺癌是妇女最常见的恶性肿瘤，也是第二大致死性疾病。为了更好地了解细胞介质在乳腺癌进展中的作用，我们研究了CC趋化因子调节激活、正常T细胞表达和分泌（RANTES）在乳腺癌进展中的潜在参与。为此，在乳腺肿瘤细胞系和乳腺癌切片中测定RANTES表达，然后分析其在疾病不同阶段的表达的发生率和强度。我们的研究表明，高和生理相关水平的RANTES组成型产生的T47 D和MCF-7乳腺肿瘤细胞系。乳腺癌切片中RANTES表达的分析表明RANTES在上皮肿瘤细胞中表达的发生率很高; 74%的切片中表达了趋化因子。RANTES表达很少检测到正常导管上皮细胞或上皮细胞，构成良性乳腺肿块，这是位于肿瘤细胞附近。在大多数II期和III期乳腺癌患者的切片中检测到RANTES表达的高发生率和强度（分别检测到83%和83.3%的表达），而在I期乳腺癌患者的切片中RANTES表达的发生率和强度较低（55%的病例）。最重要的是，在诊断为良性乳腺疾病的患者和接受乳房缩小术的女性（15.4%的病例）的切片中，RANTES的表达最低限度。这些结果表明RANTES的表达与疾病的更晚期直接相关，表明RANTES可能参与乳腺癌的进展。此外，在诊断为良性乳腺疾病的患者中，RANTES表达可能指示正在进行但尚未检测到的恶性过程。
Breast carcinoma is the most common malignant disease among women and the second most lethal one. In search for a better understanding of the role of cellular mediators in the progression of this disease, we investigated the potential involvement of the CC chemokine Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) in breast carcinoma progression. To this end, RANTES expression was determined in breast tumor cell lines and in sections of breast carcinomas, followed by analysis of the incidence and intensity of its expression in different stages of the disease. Our study reveals that high and physiologically relevant levels of RANTES are constitutively produced by T47D and MCF-7 breast tumor cell lines. Analysis of RANTES expression in sections of breast carcinomas demonstrates a high incidence of RANTES expression in epithelial tumor cells; the chemokine was expressed in 74% of the sections. RANTES expression was rarely detected in normal duct epithelial cells or in epithelial cells that constitute benign breast lumps, which were located in proximity to tumor cells. High incidence and intensity of RANTES expression were detected in sections of most of the patients with stage II and stage III of the disease (expression was detected in 83 and 83.3%, respectively), whereas RANTES was expressed at a lower incidence and intensity in sections of patients with stage I of breast carcinoma (55% of the cases). Most importantly, the expression of RANTES was minimally detected in sections of patients diagnosed with benign breast disorders and of women that underwent reduction mammoplasty (15.4% of the cases). These results indicate that the expression of RANTES is directly correlated with a more advanced stage of disease, suggesting that RANTES may be involved in breast cancer progression. Moreover, it is possible that in patients diagnosed with benign breast disorders, RANTES expression may be indicative of an ongoing, but as yet undetectable, malignant process.